Your session is about to expire
← Back to Search
Infusion of NEXI-001 T Cells for Acute Myeloid Leukemia
Study Summary
This trial is being done to study a new experimental therapy, NEXI-001, which is a T cell product targeting multiple leukemia associated antigen peptides, in patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome who have relapsed disease after an allogeneic hematopoietic cell transplant.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many subjects are enrolled in this research?
"In order to move forward, this trial requires 22 willing and eligible participants. The specified inclusion criteria must be met by potential patients who can inquire about the trial at locations like Advent Health Medical Group Blood & Marrow Transplant in Orlando, Florida or City of Hope Comprehensive Cancer Center in Duarte, California."
In how many different medical clinics is this medical study being run today?
"This clinical trial is presently being conducted at 5 sites. The locations are based in Orlando, Duarte and New york along with other locations. To minimize travel requirements, participants should select the clinic closest to them."
Are patients currently being enrolled in this research?
"That is correct. The clinicaltrials.gov website has the most recent update which was on February 16th, 2021 and it states that the study is still looking for 22 individuals who meet the requirements. There are 5 locations where you could potentially participate in this trial."
Share this study with friends
Copy Link
Messenger